6.08
Phathom Pharmaceuticals Inc stock is traded at $6.08, with a volume of 1.65M.
It is up +9.75% in the last 24 hours and up +5.56% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$5.54
Open:
$5.675
24h Volume:
1.65M
Relative Volume:
1.50
Market Cap:
$397.63M
Revenue:
-
Net Income/Loss:
$-297.11M
P/E Ratio:
-1.1715
EPS:
-5.19
Net Cash Flow:
$-216.95M
1W Performance:
+21.60%
1M Performance:
+5.56%
6M Performance:
-67.52%
1Y Performance:
-29.47%
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PHAT
Phathom Pharmaceuticals Inc
|
6.08 | 397.63M | 0 | -297.11M | -216.95M | -5.19 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-14-25 | Initiated | Cantor Fitzgerald | Overweight |
May-03-24 | Initiated | Stifel | Buy |
Jan-05-24 | Reiterated | Needham | Buy |
Aug-09-23 | Initiated | H.C. Wainwright | Buy |
May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
Mar-13-23 | Initiated | Craig Hallum | Buy |
Oct-21-22 | Initiated | Jefferies | Buy |
May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
May-12-21 | Upgrade | Goldman | Sell → Neutral |
Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
Feb-02-21 | Initiated | Guggenheim | Buy |
Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
Nov-20-19 | Initiated | Evercore ISI | Outperform |
Nov-19-19 | Initiated | Goldman | Neutral |
Nov-19-19 | Initiated | Jefferies | Buy |
Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
Jefferies cuts Phathom Pharmaceuticals target to $13 By Investing.com - Investing.com UK
Jefferies Cuts Price Target on Phathom Pharmaceuticals to $13 From $17, Maintains Buy Rating - Marketscreener.com
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.17 Average Price Target from Brokerages - Defense World
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Purchased by Keybank National Association OH - Defense World
Phathom Pharmaceuticals stock hits 52-week low at $4.34 - Investing.com
Phathom Pharmaceuticals stock hits 52-week low at $4.34 By Investing.com - Investing.com Australia
Insider Buying: Asit Parikh Acquires 10,000 Shares of Phathom Ph - GuruFocus.com
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic? - Simply Wall St
Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $12.00 at The Goldman Sachs Group - Defense World
Phathom Pharmaceuticals’ Earnings Call: Growth and Challenges - TipRanks
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Position Boosted by Rhumbline Advisers - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from HC Wainwright - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Needham & Company LLC - Defense World
Phathom Pharmaceuticals price target lowered to $12 from $18 at Goldman Sachs - TipRanks
Phathom Pharmaceuticals price target lowered to $19 from $27 at Craig-Hallum - TipRanks
H.C. Wainwright maintains $28 target on Phathom Pharma stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $28 target on Phathom Pharma stock - Investing.com
Phathom Pharmaceuticals: Strategic Positioning and Growth Potential in GERD Market Drives Buy Rating - TipRanks
Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ... - Yahoo Finance
Phathom Pharmaceuticals Reports Strong Growth with VOQUEZNA - TipRanks
Phathom Pharmaceuticals: Strong Performance and Optimistic Outlook Amidst Patent Uncertainty - TipRanks
Stifel maintains Buy on Phathom stock with $28 target - Investing.com India
Stifel maintains Buy on Phathom stock with $28 target By Investing.com - Investing.com South Africa
Earnings call transcript: Phathom Pharma Q4 2024 sees 81% revenue rise - Investing.com UK
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Phathom Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Phathom Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result - GuruFocus.com
Phathom Pharmaceuticals stock hits 52-week low at $5.21 - Investing.com
Phathom Pharmaceuticals stock hits 52-week low at $5.21 By Investing.com - Investing.com Canada
(PHAT) Investment Analysis and Advice - Stock Traders Daily
Phathom Pharmaceuticals (PHAT) Expected to Announce Earnings on Thursday - MarketBeat
Cantor Fitzgerald Upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) to Strong-Buy - MarketBeat
Phathom Pharmaceuticals (PHAT) Projected to Post Quarterly Earnings on Thursday - Defense World
Phathom Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 - The Manila Times
Phathom Pharmaceuticals to Host Conference Call on March 6, 2025, for Fourth Quarter and Full Year 2024 Financial Results - Nasdaq
Can Phathom's VOQUEZNA Sales Drive Q4 Growth? Earnings Call Set for March 6 - StockTitan
How to Take Advantage of moves in (PHAT) - Stock Traders Daily
Phathom Pharmaceuticals CFO Molly Henderson sells shares worth $43,370 - MSN
Cantor Fitzgerald Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - MarketBeat
Phathom spikes as Cantor Fitzgerald bullish on IP claims - MSN
Cantor Fitzgerald Initiates Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phathom Pharmaceuticals Inc Stock (PHAT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Henderson Molly | CFO and CBO |
Jan 21 '25 |
Sale |
6.59 |
6,583 |
43,371 |
93,546 |
Nabulsi Azmi | Chief Operating Officer |
Jan 21 '25 |
Sale |
6.59 |
7,886 |
51,957 |
233,390 |
Curran Terrie | President and Chief Executive |
Jan 21 '25 |
Sale |
6.59 |
19,109 |
125,884 |
360,465 |
Nabulsi Azmi | Chief Operating Officer |
Dec 19 '24 |
Sale |
8.00 |
1,118 |
8,944 |
239,303 |
Henderson Molly | CFO and CBO |
Dec 19 '24 |
Sale |
8.00 |
1,291 |
10,328 |
98,156 |
KARBE FRANK | Director |
Dec 13 '24 |
Buy |
7.93 |
12,500 |
99,084 |
57,000 |
Parikh Asit | Director |
Dec 13 '24 |
Buy |
8.12 |
10,000 |
81,248 |
75,500 |
Nabulsi Azmi | Chief Operating Officer |
Jul 15 '24 |
Sale |
11.72 |
10,901 |
127,760 |
240,421 |
Henderson Molly | CFO and CBO |
Jul 15 '24 |
Sale |
11.72 |
4,325 |
50,689 |
99,447 |
Curran Terrie | President and Chief Executive |
Jul 15 '24 |
Sale |
11.72 |
33,848 |
396,699 |
377,734 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):